Anavex Allegedly Hid Clinical Trial Issues Before Stock Drop

Anavex Life Sciences Corp. and CEO Christopher Missling concealed from investors that clinical trials had used different measures to assess its treatment for a neurodevelopmental disorder, a proposed shareholder class action says.

The drugmaker publicly stated that it would use the same metrics in both its “Avatar” and “Excellence” studies of blarcamesine to treatRett Syndrome, a neurodevelopmental disorder that primarily affects females. But the company later revealed in its trial results that it hadn’t measured the outcomes of both trials in the same way, according to the complaint filed Wednesday in US District Court for the Southern District of New ...